Category: Private Citizen — Corporate Director Role: Independent Director, Altria Group Inc. Board Tenure: 2020 – present Committee Memberships: Audit Committee; Executive Committee; Innovation Committee (Chair); Nominating, Corporate Governance & Social Responsibility (NCGSR) Committee Profile Type: Board Member Accountability — Anchor B (Documented Organizational Leadership)

Basis for Inclusion: Ellen R. Strahlman holds a documented governance role at Altria Group Inc. Altria Group Inc. is the parent company of Philip Morris USA, the maker of Marlboro cigarettes, and has made significant documented political donations to Trump-aligned entities. Altria’s business is substantially affected by FDA tobacco regulation, federal excise tax policy, and the regulatory framework governing menthol cigarettes, oral nicotine, and e-cigarettes. This profile documents the factual governance relationship, not the subject’s personal political views.

Subject Classification: Private Citizen / Corporate Director. Board membership is a matter of public record.

What is NOT the basis for inclusion: Personal political opinions, party affiliation, or protected speech are NOT the basis for inclusion.

Biographical Overview

Ellen R. Strahlman is a physician-scientist and medical executive with senior leadership experience in pharmaceutical and medical technology R&D. She served as Executive Vice President of Research and Development and Chief Medical Officer at Becton, Dickinson and Company (BD), a major global medical device and diagnostics company, where she led clinical research, regulatory science, and innovation strategy. Previously, she served as Chief Medical Officer at GlaxoSmithKline (GSK), one of the world’s largest pharmaceutical companies, with global responsibility for clinical safety and medical affairs. Her background in managing regulated biomedical research and working with the FDA directly informs her role on Altria’s Innovation Committee, which oversees the company’s reduced-risk product development strategy including oral nicotine pouches and e-vapor products. Strahlman chairs the Innovation Committee and joined the Altria board in 2020.

Board Role and Governance Authority

• Company: Altria Group Inc. (NYSE: MO)
• Board tenure: 2020 – present
• Committee assignments: Audit Committee; Executive Committee; Innovation Committee (Chair); Nominating, Corporate Governance & Social Responsibility (NCGSR) Committee
• Note: As Innovation Committee Chair, Strahlman oversees Altria’s strategy for reduced-risk tobacco and nicotine products — the core of Altria’s FDA regulatory engagement.

Other Current Board Memberships (if applicable)

Not separately disclosed in the 2025 DEF 14A proxy beyond Altria service.

Parent Corporate Donor Profile

This profile is a governance-accountability companion to the Altria Group corporate donor profile.

Factual correction requests: If you believe information in this profile is incorrect, please contact factcheck@patriot.university with your name (optional), the specific claim, and any supporting documentation. We review all submissions and correct verified errors promptly.

Investigative trail pointers (public records)

Education only — verify independently. Absence of hits is not proof.

Use public-records-research-specialist, corporate-intelligence-investigator, and public-corruption-ombudsman evidence tiers.

Sources

• Altria Group Inc. DEF 14A Proxy Statement, filed April 3, 2025; SEC EDGAR (CIK 764180)
• SEC EDGAR filing: https://www.sec.gov/Archives/edgar/data/764180/000155837025004359/tmb-20250515xdef14a.htm